380629-65-2

Basic information

• Product Name: Carbamic acid, [(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-, 1,1-dimethylethyl ester
• CAS NO: 380629-65-2
• Molecular Formula: C18H26N2O3
• Molecular Weight: 318.416
• Mol File: 380629-65-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-, 1,1-dimethylethyl ester(380629-65-2)
• EPA Substance Registry System: Carbamic acid, [(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-, 1,1-dimethylethyl ester(380629-65-2)

Safety Data

• Hazardous Substances Data: 380629-65-2(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1389338-67-3 C₂₀H₂₈N₂O₃ 
• 90600-20-7 (2S)-2-[(tert-butoxycarbonyl)amino]pent-4-enoic acid 
• 21568-87-6 2-aminocaprolactam 
• 2389-45-9 Boc-Lys(Z)-OH 
• 1055423-27-2 (3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-carboxylic acid phenylmethyl ester 
• 100-39-0 benzyl bromide 
• 76944-95-1 tert-butyl N-[(3S)-2-oxoazepan-3-yl]carbamate 

Downstream Products

• 209983-91-5 (S)-1-benzyl-2-oxo-3-amino-azepine 
• 1361322-55-5 (S)-N-((S)-1-cyclohexyl-2-oxo-2-((S)-1-phenethylazepan-3-ylamino)ethyl)-2-(methylamino)propanamide 
• 1361323-06-9 tert-butyl (S)-1-((S)-1-cyclohexyl-2-oxo-2-((S)-1-phenethylazepan-3-ylamino)ethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-54-4 (S)-N-((S)-2-((S)-1-benzylazepan-3-ylamino)-1-cyclohexyl-2-oxoethyl)-2-(methylamino)propanamide 
• 1361323-05-8 tert-butyl (S)-1-((S)-2-((S)-1-benzylazepan-3-ylamino)-1-cyclohexyl-2-oxoethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361378-83-7 (S)-2-amino-N-((S)-1-benzylazepan-3-yl)-2-cyclohexylacetamide dihydrochloride 
• 1361323-03-6 tert-butyl (S)-2-((S)-1-benzylazepan-3-ylamino)-1-cyclohexyl-2-oxoethylcarbamate 
• 625471-23-0 (S)-1-benzylazepan-3-amine 
• 202819-52-1 (RS)-3-amino-2-oxo-1-benzyl-azepine 
• 635754-92-6 (S)-4-{[(1-trityl-1H-imidazol-4-ylmethyl)-(1-benzyl-2-oxo-azepan-3-yl)-amino]-methyl}-benzonitrile 
• 635754-91-5 (S)-1-benzyl-3-[(1-trityl-imidazol-4-ylmethyl)amino]-azepan-2-one 

Relevant articles and documents

Ring-closing metathesis based total synthesis of ciliatamides A and B and their structural confirmation

Protecting group dependant ring-closing metathesis based approach to the total synthesis of the revised structures of ciliatamides A and B has been described. The current synthetic strategy utilizes the amino acid as starting material to introduce both the stereogenic centers. However, usage of non-racemizing reagents (EDC·HCl, HATU/NMM); for amide coupling and Grubbs' second generation catalyst for caprolactam ring synthesis makes the present approach more convenient to get the correct conclusion on absolute stereochemistry. Thus, on the basis of similar optical rotation values with the Lindsley's reported data, this synthesis further supported for the actual stereochemistry of both ciliatamides A and B is (R,R).

Discovery of aminopiperidine-based Smac mimetics as IAP antagonists

A series of structurally unique Smac mimetics that act as antagonists of inhibitor of apoptosis proteins (IAPs) has been discovered. While most previously described Smac mimetics contain the proline ring (or a similar cyclic motif) found in Smac, a key feature of the compounds described herein is that this ring has been removed. Despite this, compounds in this series potently bind to cIAP1 and elicit the expected phenotype of cIAP1 inhibition in cancer cells. Marked selectivity for cIAP1 over XIAP is observed for these compounds, which is attributed to a slight difference in the binding groove between the two proteins and the resulting steric interactions with the inhibitors. XIAP binding can be improved by constraining the inhibitor so that these unfavorable steric interactions are minimized.

SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS

The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b), enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated